Company intelligence / Profile preview
Baiyu Pharmaceutical
Chengdu, Sichuan, Chinabaiyu.cn ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Baiyu’s lead candidate BY101298, an oral small molecule DNA-PK inhibitor, is in Phase II trials for malignant solid tumors in China. PARP7 inhibitor BY101921 is in Phase I trials. Its marketed ginkgolide injection (botanical drug) is widely sold in China. A $1.1B global licensing deal with Novartis validates its oncology pipeline[2][4][5][8][10].
- Therapeutic areas
- OncologyNeurologyCardiovascular
- Modalities
- Small moleculeHerbal medicineProteolysis-targeting chimera therapyMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Baiyu Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baiyu Pharmaceutical.